The US still doesn’t have the data we need to make informed decisions on booster shots

Last fall, I wrote that the U.S. did not have the data we needed to make informed decisions about booster shots. Several months later, we still don’t have the data we need, as questions about a potential BA.2 wave and other future variants abound. Discussions at a recent FDA advisory committee meeting made these data gaps clear.

Read More

We failed to vaccinate the world in 2021; will 2022 be more successful?

In January, COVAX set a goal that many global health advocates considered modest: delivering 2.3 billion vaccine doses to low- and middle-income countries by the end of 2021. is saying it’ll deliver just 800 million vaccine doses by the end of 2021, according to the Washington Post, and only about 600 million had been delivered by early December.

Read More

One month into vaccinations for kids 5-11, uptake varies wildly by state

It’s been about a month since the FDA and CDC authorized a version of Pfizer’s vaccine for children ages five to 11. Those kids whose parents immediately took them to get vaccinated are now eligible for their second doses, and will be considered fully vaccinated by Christmas. Despite widespread availability of the shots, vaccine uptake has varied wildly.

Read More